| Year |
Citation |
Score |
| 2020 |
Sharma P, Roberts C, Herpai D, Fokt ID, Priebe W, Debinski W. Drug Conjugates for Targeting Eph Receptors in Glioblastoma. Pharmaceuticals (Basel, Switzerland). 13. PMID 32340173 DOI: 10.3390/Ph13040077 |
0.306 |
|
| 2020 |
Zielinski R, Grela K, Skora S, Fokt I, Sander M, Didluch A, Priebe W. Abstract P2-15-03: Liposomal annamycin inhibition of lung localized breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P2-15-03 |
0.341 |
|
| 2019 |
Zielinski R, Grela K, Skora S, Jacamo R, Fokt I, Sander M, Remiszewski M, Felix E, Shanmugasundaram M, Zal MA, Andreeff M, Priebe W, Zal T. Biodistribution and Efficacy of L-Annamycin in a Novel Imageable AML Mouse Model Blood. 134: 5150-5150. DOI: 10.1182/Blood-2019-131977 |
0.31 |
|
| 2019 |
Zielinski R, Fokt I, Skora S, Felix E, Grela K, Arumugam J, Venugopal R, Ai M, Hartley G, Curran M, Priebe W. Abstract 4799: Inhibition of STAT3 in pancreatic ductal adenocarcinoma and immunotherapeutic implications Cancer Research. 79: 4799-4799. DOI: 10.1158/1538-7445.Am2019-4799 |
0.359 |
|
| 2019 |
Zielinski R, Zal T, Grela K, Skora S, Fokt I, Sander M, Remiszewski M, Felix E, Shanmugasundaram M, Priebe W. Abstract C094: Dose and schedule-dependent efficacy of liposomal Annamycin in pre-clinical models of acute myeloid leukemia Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-C094 |
0.35 |
|
| 2018 |
Basu H, Wilganowski N, Lieblich J, Wu G, Fokt I, Ramachandran S, Yu J, Titus M, Priebe W, Beebe DJ, Wilding G. Abstract B091: Small-molecule inhibitors targeting a specific metabolic pathway for precision therapy of advanced castrate-resistant prostate cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Prca2017-B091 |
0.335 |
|
| 2018 |
Basu HS, Wilgonowski NL, Lieblich JL, Wu GT, Fokt I, Ramachandran S, Yu J, Titus M, Priebe W, Beebe DJ, Wilding G. Abstract 3846: A metabolic pathway targeted inhibitor for precision therapy of castrate-resistant prostate cancer Cancer Research. 78: 3846-3846. DOI: 10.1158/1538-7445.Am2018-3846 |
0.351 |
|
| 2017 |
Olbryt M, Rusin A, Fokt I, Habryka A, Tudrej P, Student S, Sochanik A, Zieliński R, Priebe W. Bis-anthracycline WP760 abrogates melanoma cell growth by transcription inhibition, p53 activation and IGF1R downregulation. Investigational New Drugs. 35: 545-555. PMID 28417283 DOI: 10.1007/S10637-017-0465-9 |
0.36 |
|
| 2016 |
Santoro M, Menegaz BA, Lamhamedi-Cherradi SE, Molina ER, Wu D, Priebe W, Ludwig JA, Mikos AG. MODELING STROMA-INDUCED DRUG RESISTANCE IN A TISSUE-ENGINEERED TUMOR MODEL OF EWING SARCOMA. Tissue Engineering. Part A. PMID 27923328 DOI: 10.1089/Ten.Tea.2016.0369 |
0.325 |
|
| 2016 |
Shingu T, Holmes L, Henry V, Wang Q, Latha K, Gururaj AE, Gibson LA, Doucette T, Lang FF, Rao G, Yuan L, Sulman EP, Farrell NP, Priebe W, Hess KR, et al. Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells. Journal of Translational Medicine. 14: 46. PMID 26861698 DOI: 10.1186/S12967-016-0803-2 |
0.303 |
|
| 2015 |
Mansilla S, Vizcaíno C, Rodríguez-Sánchez MA, Priebe W, Portugal J. Autophagy modulates the effects of bis-anthracycline WP631 on p53-deficient prostate cancer cells. Journal of Cellular and Molecular Medicine. 19: 786-98. PMID 25689150 DOI: 10.1111/Jcmm.12402 |
0.313 |
|
| 2015 |
Shingu T, Holmes L, Henry V, Latha K, Gururaj AE, Gibson LA, Doucette T, Lang FF, Rao G, Yuan L, Sulman EP, Farrell NP, Priebe W, Hess KR, Wang YA, et al. Abstract 3483: Synergistic combination therapy with molecular targeted drugs in glioma stem-like cells Cancer Research. 75: 3483-3483. DOI: 10.1158/1538-7445.Am2015-3483 |
0.334 |
|
| 2015 |
Zielinski R, Skora S, Rusin A, Fokt I, Heimberger A, Sawaya R, Priebe W. ATPS-68COMBINATION OF TOPOISOMERASE II POISON BERUBICIN WITH STAT3 INHIBITOR WP1066BLOCKS POTENTLY TUMOR GROWTH IN GMB MODELS Neuro-Oncology. 17: v33.2-v33. DOI: 10.1093/Neuonc/Nov204.68 |
0.357 |
|
| 2014 |
Mielecki M, Milner-Krawczyk M, Grzelak K, Mielecki D, Krzysko KA, Lesyng B, Priebe W. Analogs of cinnamic acid benzyl amide as nonclassical inhibitors of activated JAK2 kinase. Current Cancer Drug Targets. 14: 638-51. PMID 25146330 DOI: 10.2174/1568009614666140821122718 |
0.33 |
|
| 2014 |
Tsourdinis G, Park H, Sun L, Fokt I, Jayakumar A, Zhang H, Cai Q, Zou D, Fang B, Priebe W, Wang M, Zhang L. Potent Inhibition of the Growth and Induction of Apoptosis of Mantle Cell Lymphoma By the Novel Anthracycline Berubicin in Vitro and in Vivo Blood. 124: 3106-3106. DOI: 10.1182/Blood.V124.21.3106.3106 |
0.352 |
|
| 2014 |
Jayakumar A, Radjendirane V, Fleming J, Kang Y, Rusin A, Zielinski R, Skora S, Fokt I, Priebe W. Abstract 2946: Status of STAT3, STAT5, and NF-κB in pancreatic cancer cell lines, small molecule inhibitors, and potential clinical implications Cancer Research. 74: 2946-2946. DOI: 10.1158/1538-7445.Am2014-2946 |
0.336 |
|
| 2013 |
Garnett J, Chumbalkar V, Vaillant B, Gururaj AE, Hill KS, Latha K, Yao J, Priebe W, Colman H, Elferink LA, Bogler O. Regulation of HGF expression by ΔEGFR-mediated c-Met activation in glioblastoma cells. Neoplasia (New York, N.Y.). 15: 73-84. PMID 23359207 DOI: 10.1593/Neo.121536 |
0.312 |
|
| 2013 |
Jayakumar A, Rauvolfova J, Bao H, Fokt I, Skora S, Heimberger A, Priebe W. Abstract 3251: Blockade of HIF-1 with a small molecule inhibitor WP1066 in melanoma. Cancer Research. 73: 3251-3251. DOI: 10.1158/1538-7445.Am2013-3251 |
0.321 |
|
| 2012 |
Doucette TA, Kong LY, Yang Y, Ferguson SD, Yang J, Wei J, Qiao W, Fuller GN, Bhat KP, Aldape K, Priebe W, Bögler O, Heimberger AB, Rao G. Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. Neuro-Oncology. 14: 1136-45. PMID 22753228 DOI: 10.1093/Neuonc/Nos139 |
0.305 |
|
| 2012 |
Swiatek-Machado K, Mieczkowski J, Ellert-Miklaszewska A, Swierk P, Fokt I, Szymanski S, Skora S, Szeja W, Grynkiewicz G, Lesyng B, Priebe W, Kaminska B. Novel small molecular inhibitors disrupt the JAK/STAT3 and FAK signaling pathways and exhibit a potent antitumor activity in glioma cells. Cancer Biology & Therapy. 13: 657-70. PMID 22555804 DOI: 10.4161/Cbt.20083 |
0.357 |
|
| 2012 |
Sai K, Wang S, Balasubramaniyan V, Conrad C, Lang FF, Aldape K, Szymanski S, Fokt I, Dasgupta A, Madden T, Guan S, Chen Z, Alfred Yung WK, Priebe W, Colman H. Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway. Journal of Neuro-Oncology. 107: 487-501. PMID 22249692 DOI: 10.1007/S11060-011-0786-Z |
0.359 |
|
| 2012 |
Hatiboglu MA, Kong LY, Wei J, Wang Y, McEnery KA, Fuller GN, Qiao W, Davies MA, Priebe W, Heimberger AB. The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. International Journal of Cancer. Journal International Du Cancer. 131: 8-17. PMID 21792892 DOI: 10.1002/Ijc.26307 |
0.321 |
|
| 2012 |
Wang M, Sun L, Fokt I, Zhang L, Jayakumar A, Priebe W. Effect of berubicin, the 4'-o-benzylated doxorubicin analog, on growth inhibition and apoptosis in multiple myeloma. Journal of Clinical Oncology. 30: e18557-e18557. DOI: 10.1200/Jco.2012.30.15_Suppl.E18557 |
0.32 |
|
| 2012 |
Chen X, Fokt I, Skora S, Priebe W, Bi Y, Tang DG, Yan H, Zhang Q, Qin J, Li H, Liu C, Davis T, Coletta LD, Klostergaard J. Abstract C65: Drug-tolerant cancer cells show reduced tumor-initiating capacity: Depletion of CD44+ cells and evidence for epigenetic mechanisms Cancer Research. 72: C65-C65. DOI: 10.1158/1538-7445.Prca2012-C65 |
0.331 |
|
| 2012 |
Sevier AH, Zagorodna O, Martin SM, Priebe W, Knudson CM. Abstract LB-250: 2-Deoxy-D-glucose cytotoxicity relies on both glycolysis inhibition and ER stress induction, and is efficacious in a variety of human lymphoma models Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-250 |
0.33 |
|
| 2012 |
Priebe W, Kato T, Fokt I, Madden TL, Conrad CA, Johansen MJ, Skora S, Nguyen VN, Arumugam J. Abstract 1804: Novel gold derivatives of thiosugars potently inhibit p-STAT3 and downregulate HIF-1α in ependymomas Cancer Research. 72: 1804-1804. DOI: 10.1158/1538-7445.Am2012-1804 |
0.359 |
|
| 2011 |
Yan H, Chen X, Zhang Q, Qin J, Li H, Liu C, Calhoun-Davis T, Coletta LD, Klostergaard J, Fokt I, Skora S, Priebe W, Bi Y, Tang DG. Drug-tolerant cancer cells show reduced tumor-initiating capacity: depletion of CD44 cells and evidence for epigenetic mechanisms. Plos One. 6: e24397. PMID 21935404 DOI: 10.1371/Journal.Pone.0024397 |
0.325 |
|
| 2011 |
Atkinson JM, Shelat AA, Carcaboso AM, Kranenburg TA, Arnold LA, Boulos N, Wright K, Johnson RA, Poppleton H, Mohankumar KM, Féau C, Phoenix T, Gibson P, Zhu L, Tong Y, ... ... Priebe W, et al. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell. 20: 384-99. PMID 21907928 DOI: 10.1016/J.Ccr.2011.08.013 |
0.308 |
|
| 2011 |
Wei J, Wu A, Kong LY, Wang Y, Fuller G, Fokt I, Melillo G, Priebe W, Heimberger AB. Hypoxia potentiates glioma-mediated immunosuppression. Plos One. 6: e16195. PMID 21283755 DOI: 10.1371/Journal.Pone.0016195 |
0.326 |
|
| 2010 |
Pham LV, Tamayo AT, Li C, Bornmann W, Priebe W, Ford RJ. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications. Molecular Cancer Therapeutics. 9: 2026-36. PMID 20606045 DOI: 10.1158/1535-7163.Mct-10-0238 |
0.363 |
|
| 2010 |
He H, Nilsson CL, Emmett MR, Marshall AG, Kroes RA, Moskal JR, Ji Y, Colman H, Priebe W, Lang FF, Conrad CA. Glycomic and transcriptomic response of GSC11 glioblastoma stem cells to STAT3 phosphorylation inhibition and serum-induced differentiation. Journal of Proteome Research. 9: 2098-108. PMID 20199106 DOI: 10.1021/Pr900793A |
0.316 |
|
| 2010 |
Wei J, Barr J, Kong LY, Wang Y, Wu A, Sharma AK, Gumin J, Henry V, Colman H, Priebe W, Sawaya R, Lang FF, Heimberger AB. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Molecular Cancer Therapeutics. 9: 67-78. PMID 20053772 DOI: 10.1158/1535-7163.Mct-09-0734 |
0.32 |
|
| 2010 |
Wu AS, Wei J, Kong L, Wang Y, Priebe W, Sawaya R, Lang FF, Heimberger AB. Abstract 5322: Glioma cancer stem cells induce immune suppressive macrophages Cancer Research. 70: 5322-5322. DOI: 10.1158/1538-7445.Am10-5322 |
0.332 |
|
| 2010 |
Priebe W, Skibicki P, Neamati N, Achmatowicz O, Grynkiewicz G, Szechner B. ChemInform Abstract: Synthesis of Kedarosamine, a Sugar Portion of the Chromoprotein Antibiotic Kedarcidine. Cheminform. 30: no-no. DOI: 10.1002/chin.199942223 |
0.435 |
|
| 2010 |
PRIEBE W, GRYNKIEWICZ G, NEAMATI N. ChemInform Abstract: One-Step C-Acylation of Glycals and 2-Deoxyhexopyranoses at C-2. Cheminform. 24: no-no. DOI: 10.1002/chin.199318152 |
0.424 |
|
| 2010 |
PRIEBE W, GRYNKIEWICZ G, NEAMATI N, PEREZ-SOLER R. ChemInform Abstract: A Facile Method for Preparation of 3-Thio Sugars and 3-Thio Glycals. Synthesis of 3′-Mercapto-3′-deaminodoxorubicin. Cheminform. 23: no-no. DOI: 10.1002/chin.199215301 |
0.441 |
|
| 2010 |
PRIEBE W, GRYNKIEWICZ G, NEAMATI N. ChemInform Abstract: 2-Deoxy-1-O-Silylated β-Hexopyranoses. Useful Glycosyl Donors and Synthetic Intermediates. Cheminform. 23: no-no. DOI: 10.1002/chin.199207249 |
0.442 |
|
| 2010 |
PRIEBE W, GRYNKIEWICZ G, NEAMATI N. ChemInform Abstract: Synthesis of New 1-C-(2-Furyl)- and 3-C-(2-Furyl)-hexopyranosides and 3-C-(2-Furyl)-daunorubicin Analogs. Cheminform. 22: no-no. DOI: 10.1002/chin.199135277 |
0.433 |
|
| 2009 |
Gao H, Priebe W, Glod J, Banerjee D. Activation of signal transducers and activators of transcription 3 and focal adhesion kinase by stromal cell-derived factor 1 is required for migration of human mesenchymal stem cells in response to tumor cell-conditioned medium. Stem Cells (Dayton, Ohio). 27: 857-65. PMID 19350687 DOI: 10.1002/Stem.23 |
0.312 |
|
| 2009 |
Kong LY, Wei J, Sharma AK, Barr J, Abou-Ghazal MK, Fokt I, Weinberg J, Rao G, Grimm E, Priebe W, Heimberger AB. A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunology, Immunotherapy : Cii. 58: 1023-32. PMID 19002459 DOI: 10.1007/S00262-008-0618-Y |
0.306 |
|
| 2009 |
Samanta AK, Chakraborty SN, Sun X, Schlette E, Priebe W, Arlinghaus RB. Jak2 Phosphorylates Tyr 177 of Bcr-Abl Activating the Ras and PI-3 Kinase Pathways and Maintains Functional Levels of Bcr-Abl in Chronic Myelogenous Leukemia. Blood. 114: 39-39. DOI: 10.1182/Blood.V114.22.39.39 |
0.337 |
|
| 2009 |
Tao W, Samanta AK, Priebe W, Arlinghaus RB. Enhanced Jak2 Activation Correlates with β Chain Expression Leading to Phosphorylation of Tyrosine 177 of Bcr-Abl. Blood. 114: 2170-2170. DOI: 10.1182/Blood.V114.22.2170.2170 |
0.302 |
|
| 2009 |
Priebe W, Cybulski M, Fokt I, Skora S, Conrad CA, Madden T. Abstract C98: Blocking glycolysis with 2‐deoxy‐D‐glucose prodrugs to target brain tumors: A novel concept Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C98 |
0.349 |
|
| 2008 |
Heimberger AB, Priebe W. Small molecular inhibitors of p-STAT3: novel agents for treatment of primary and metastatic CNS cancers. Recent Patents On Cns Drug Discovery. 3: 179-88. PMID 18991807 DOI: 10.2174/157488908786242489 |
0.323 |
|
| 2008 |
Kong LY, Abou-Ghazal MK, Wei J, Chakraborty A, Sun W, Qiao W, Fuller GN, Fokt I, Grimm EA, Schmittling RJ, Archer GE, Sampson JH, Priebe W, Heimberger AB. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 5759-68. PMID 18794085 DOI: 10.1158/1078-0432.Ccr-08-0377 |
0.305 |
|
| 2007 |
Ferrajoli A, Faderl S, Van Q, Koch P, Harris D, Liu Z, Hazan-Halevy I, Wang Y, Kantarjian HM, Priebe W, Estrov Z. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Research. 67: 11291-9. PMID 18056455 DOI: 10.1158/0008-5472.Can-07-0593 |
0.335 |
|
| 2007 |
Hussain SF, Kong LY, Jordan J, Conrad C, Madden T, Fokt I, Priebe W, Heimberger AB. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Research. 67: 9630-6. PMID 17942891 DOI: 10.1158/0008-5472.Can-07-1243 |
0.307 |
|
| 2007 |
Gruber BM, Anuszewska EL, Bubko I, Goździk A, Fokt I, Priebe W. Effect of structural modification at the 4, 3', and 2' positions of doxorubicin on topoisomerase II poisoning, apoptosis, and cytotoxicity in human melanoma cells. Archivum Immunologiae Et Therapiae Experimentalis. 55: 193-8. PMID 17557149 DOI: 10.1007/S00005-007-0018-6 |
0.336 |
|
| 2007 |
Bidwell GL, Davis AN, Fokt I, Priebe W, Raucher D. A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance. Investigational New Drugs. 25: 313-26. PMID 17483874 DOI: 10.1007/S10637-007-9053-8 |
0.328 |
|
| 2007 |
Mansilla S, Rojas M, Bataller M, Priebe W, Portugal J. Circumvention of the multidrug-resistance protein (MRP-1) by an antitumor drug through specific inhibition of gene transcription in breast tumor cells. Biochemical Pharmacology. 73: 934-42. PMID 17217917 DOI: 10.1016/J.Bcp.2006.12.005 |
0.333 |
|
| 2007 |
Bartholomeusz GA, Talpaz M, Kapuria V, Kong LY, Wang S, Estrov Z, Priebe W, Wu J, Donato NJ. Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood. 109: 3470-8. PMID 17202319 DOI: 10.1182/Blood-2006-02-005579 |
0.319 |
|
| 2007 |
Brooks TA, O'Loughlin KL, Minderman H, Bundy BN, Ford LA, Vredenburg MR, Bernacki RJ, Priebe W, Baer MR. The 4′-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells Investigational New Drugs. 25: 115-122. PMID 17072745 DOI: 10.1007/S10637-006-9018-3 |
0.312 |
|
| 2007 |
Manshouri T, Golemovic M, Kantarjian HM, Cortes JE, Zhang Y, Priebe W, Estrov Z, Verstovsek S. Atiprimod Inhibits the JAK-STAT Pathway and Induces Apoptosis in Human Cells Carrying the JAK2V617F or JAK3 Mutation. Blood. 110: 3556-3556. DOI: 10.1182/Blood.V110.11.3556.3556 |
0.326 |
|
| 2006 |
Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, Fokt I, Hess K, Conrad C, Madden T, Sawaya R, Kondo S, Priebe W, Kondo Y. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene. 26: 2435-44. PMID 17043651 DOI: 10.1038/Sj.Onc.1210031 |
0.361 |
|
| 2006 |
Mansilla S, Priebe W, Portugal J. Transcriptional changes facilitate mitotic catastrophe in tumour cells that contain functional p53. European Journal of Pharmacology. 540: 34-45. PMID 16735036 DOI: 10.1016/J.Ejphar.2006.04.035 |
0.301 |
|
| 2006 |
Nussenzveig R, Manshouri T, Kantarjian H, Giles F, Cortes J, Gaikwad A, Priebe W, Estrov Z, Verstovsek S. Atiprimod Inhibits the Growth of JAK2 Tyrosine Kinase Over-Expressing Cells “In Vitro” and “Ex Vivo”. Blood. 108: 4924-4924. DOI: 10.1182/Blood.V108.11.4924.4924 |
0.34 |
|
| 2006 |
Manshouri T, Estrov Z, Quintas-Cardama A, Cortes J, Giles F, Harris D, Priebe W, Kantarjian H, Verstovsek S. WP1066 Inhibits Growth of Human Cells Carrying the JAK2 V617F Mutation. Blood. 108: 4885-4885. DOI: 10.1182/Blood.V108.11.4885.4885 |
0.338 |
|
| 2005 |
Ferrajoli A, Faderl S, Wang T, Priebe W, Kantarjian H, Talpaz M, Estrov Z. WP1066: A Novel PI-3K Inhibitor with Antileukemic Activity in Philadelphia Chromosome-Positive ALL. Blood. 106: 850-850. DOI: 10.1182/Blood.V106.11.850.850 |
0.304 |
|
| 2005 |
Bartholomeusz GA, Donato N, Estrov Z, Priebe W, Talpaz M. Activation of a Novel Proteasomal Independent Bcr/Abl Degradation Pathway by WP1130 Induces Apoptosis in CML Cells. Blood. 106: 2862-2862. DOI: 10.1182/Blood.V106.11.2862.2862 |
0.327 |
|
| 2005 |
Kong L, Kapuria V, Bartholomeusz G, Talpaz M, Priebe W, Donato NJ. Antitumor Activity and Mechanism of Action of a Novel Stat3 Inhibitor, WP1066, Against Human B-Cell Non-Hodgkin’s Lymphoma and Multiple Myeloma. Blood. 106: 1489-1489. DOI: 10.1182/Blood.V106.11.1489.1489 |
0.349 |
|
| 2004 |
Inge TH, Harris NL, Wu J, Azizkhan RG, Priebe W. WP744 is a novel anthracycline with enhanced activity against neuroblastoma. The Journal of Surgical Research. 121: 187-96. PMID 15501458 DOI: 10.1016/J.Jss.2004.03.027 |
0.331 |
|
| 2004 |
Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF, De Young LR, Lampidis TJ. 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Research. 64: 31-4. PMID 14729604 DOI: 10.1158/0008-5472.Can-03-3294 |
0.336 |
|
| 2004 |
Donato NJ, Wu J, Kong LY, Meng F, Priebe W, Talpaz M. Targeting BCR-ABL and Its Downstream Signaling Cascade as Therapy for Chronic Myelogenous Leukemia. Blood. 104: 2964-2964. DOI: 10.1182/Blood.V104.11.2964.2964 |
0.351 |
|
| 2004 |
Faderl S, Ferrajoli A, Harris D, Van Q, Priebe W, Estrov Z. WP-1034, a Novel Jak-Stat Inhibitor, Has Proapoptotic and Antileukemic Activity in Acute Myeloid Leukemia (AML) Cell Lines and AML Patient Samples. Blood. 104: 2528-2528. DOI: 10.1182/Blood.V104.11.2528.2528 |
0.337 |
|
| 2004 |
Ferrajoli A, Faderl S, Van Q, Harris DM, Priebe W, Kantarjian HM, Talpaz M, Estrov Z. WP-1066, a Next-Generation Member of JAK-Stat Inhibitors, Induces Cell Cycle Arrest, Abrogates Proliferation, and Induces Apoptosis of Acute Myeloid Leukemia (AML) Cells. Blood. 104: 1169-1169. DOI: 10.1182/Blood.V104.11.1169.1169 |
0.334 |
|
| 2003 |
Fuks L, Samochocka K, Anulewicz-Ostrowska R, Kruszewski M, Priebe W, Lewandowski W. Structure and biological activity of cationic [PtLCl(DMSO)]NO(3).DMSO complex containing a chelated diaminosugar: methyl-3,4-diamino-2,3,4,6-tetradeoxy-alpha-L-lyxopyranoside. European Journal of Medicinal Chemistry. 38: 775-80. PMID 12932909 DOI: 10.1016/S0223-5234(03)00139-9 |
0.314 |
|
| 2003 |
Haj HT, Salerno M, Priebe W, Kozlowski H, Garnier-Suillerot A. New findings in the study on the intercalation of bisdaunorubicin and its monomeric analogues with naked and nucleus DNA. Chemico-Biological Interactions. 145: 349-58. PMID 12732461 DOI: 10.1016/S0009-2797(03)00061-9 |
0.302 |
|
| 2003 |
Kruszewski M, Bouzyk E, Oldak T, Samochocka K, Fuks L, Lewandowski W, Fokt I, Priebe W. Differential toxic effect of cis-platinum(II) and palladium(II) chlorides complexed with methyl 3,4-diamine-2,3,4,6-tetradeoxy-alpha-L-lyxo-hexopyranoside in mouse lymphoma cell lines differing in DSB and NER repair ability. Teratogenesis, Carcinogenesis, and Mutagenesis. 1-11. PMID 12616592 DOI: 10.1002/Tcm.10046 |
0.338 |
|
| 2003 |
Villamarín S, Mansilla S, Ferrer-Miralles N, Priebe W, Portugal J. A comparative analysis of the time-dependent antiproliferative effects of daunorubicin and WP631. European Journal of Biochemistry. 270: 764-70. PMID 12581216 DOI: 10.1046/J.1432-1033.2003.03442.X |
0.306 |
|
| 2002 |
Liu H, Savaraj N, Priebe W, Lampidis TJ. Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C). Biochemical Pharmacology. 64: 1745-51. PMID 12445863 DOI: 10.1016/S0006-2952(02)01456-9 |
0.349 |
|
| 2002 |
Salerno M, Przewloka T, Fokt I, Priebe W, Garnier-Suillerot A. Preferential efflux by P-glycoprotein, but not MRP1, of compounds containing a free electron donor amine. Biochemical Pharmacology. 63: 1471-9. PMID 11996888 DOI: 10.1016/S0006-2952(02)00895-X |
0.308 |
|
| 2002 |
Villamarín S, Ferrer-Miralles N, Mansilla S, Priebe W, Portugal J. Induction of G(2)/M arrest and inhibition of c-myc and p53 transcription by WP631 in Jurkat T lymphocytes. Biochemical Pharmacology. 63: 1251-8. PMID 11960601 DOI: 10.1016/S0006-2952(02)00865-1 |
0.333 |
|
| 2001 |
Loetchutinat C, Heywang C, Priebe W, Garnier-Suillerot A. The absence of stereoselective P-glycoprotein- and multidrug resistance-associated protein-mediated transport of daunorubicin. Biochemical Pharmacology. 62: 561-7. PMID 11585053 DOI: 10.1016/S0006-2952(01)00703-1 |
0.304 |
|
| 2001 |
Loetchutinat C, Priebe W, Garnier-Suillerot A. Drug sequestration in cytoplasmic organelles does not contribute to the diminished sensitivity of anthracyclines in multidrug resistant K562 cells. European Journal of Biochemistry. 268: 4459-67. PMID 11502206 DOI: 10.1046/J.1432-1327.2001.02370.X |
0.315 |
|
| 2001 |
Liu H, Hu YP, Savaraj N, Priebe W, Lampidis TJ. Hypersensitization of tumor cells to glycolytic inhibitors. Biochemistry. 40: 5542-7. PMID 11331019 DOI: 10.1021/Bi002426W |
0.343 |
|
| 2001 |
Garnier-Suillerot A, Marbeuf-Gueye C, Salerno M, Loetchutinat C, Fokt I, Krawczyk M, Kowalczyk T, Priebe W. Analysis of drug transport kinetics in multidrug-resistant cells: implications for drug action. Current Medicinal Chemistry. 8: 51-64. PMID 11172692 DOI: 10.2174/0929867013373967 |
0.331 |
|
| 2001 |
Portugal J, Martín B, Vaquero A, Ferrer N, Villamarín S, Priebe W. Analysis of the effects of daunorubicin and WP631 on transcription. Current Medicinal Chemistry. 8: 1-8. PMID 11172687 DOI: 10.2174/0929867013373976 |
0.323 |
|
| 2000 |
Hu YP, Moraes CT, Savaraj N, Priebe W, Lampidis TJ. ρ0 Tumor cells: A model for studying whether mitochondria are targets for rhodamine 123, doxorubicin, and other drugs Biochemical Pharmacology. 60: 1897-1905. PMID 11108806 DOI: 10.1016/S0006-2952(00)00513-X |
0.344 |
|
| 1999 |
Marbeuf-Gueye C, Ettori D, Priebe W, Kozlowski H, Garnier-Suillerot A. Correlation between the kinetics of anthracycline uptake and the resistance factor in cancer cells expressing the multidrug resistance protein or the P-glycoprotein. Biochimica Et Biophysica Acta. 1450: 374-84. PMID 10395948 DOI: 10.1016/S0167-4889(99)00060-9 |
0.318 |
|
| 1998 |
Priebe W, Krawczyk M, Kuo MT, Yamane Y, Savaraj N, Ishikawa T. Doxorubicin- and daunorubicin-glutathione conjugates, but not unconjugated drugs, competitively inhibit leukotriene C4 transport mediated by MRP/GS-X pump. Biochemical and Biophysical Research Communications. 247: 859-63. PMID 9647783 DOI: 10.1006/Bbrc.1998.8887 |
0.33 |
|
| 1998 |
Marbeuf-Gueye C, Broxterman HJ, Dubru F, Priebe W, Garnier-Suillerot A. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells. Molecular Pharmacology. 53: 141-7. PMID 9443942 DOI: 10.1124/Mol.53.1.141 |
0.304 |
|
| 1997 |
Robinson H, Priebe W, Chaires JB, Wang AHJ. Binding of two novel bisdaunorubicins to DNA studied by NMR spectroscopy Biochemistry. 36: 8663-8670. PMID 9289011 DOI: 10.1021/Bi970842J |
0.322 |
|
| 1997 |
Perez-Soler R, Neamati N, Zou Y, Schneider E, Doyle LA, Andreeff M, Priebe W, Ling YH. Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide. International Journal of Cancer. 71: 35-41. PMID 9096663 DOI: 10.1002/(Sici)1097-0215(19970328)71:1<35::Aid-Ijc8>3.0.Co;2-4 |
0.529 |
|
| 1997 |
Lampidis TJ, Kolonias D, Podona T, Israel M, Safa AR, Lothstein L, Savaraj N, Tapiero H, Priebe W. Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge. Biochemistry. 36: 2679-85. PMID 9054575 DOI: 10.1021/Bi9614489 |
0.301 |
|
| 1997 |
Chaires JB, Leng F, Przewloka T, Fokt I, Ling YH, Perez-Soler R, Priebe W. Structure-based design of a new bisintercalating anthracycline antibiotic Journal of Medicinal Chemistry. 40: 261-266. PMID 9022792 DOI: 10.1021/Jm9607414 |
0.317 |
|
| 1996 |
Gao YG, Priebe W, Wang AH. Substitutions at C2' of daunosamine in the anticancer drug daunorubicin alter its DNA-binding sequence specificity. European Journal of Biochemistry. 240: 331-5. PMID 8841395 DOI: 10.1111/J.1432-1033.1996.0331H.X |
0.34 |
|
| 1996 |
Consoli U, Priebe W, Ling Y, Mahadevia R, Griffin M, Zhao S, Perez-Soler R, Andreeff M. The novel anthracycline annamycin is not affected by P-glycoprotein- related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines Blood. 88: 633-644. DOI: 10.1182/Blood.V88.2.633.Bloodjournal882633 |
0.331 |
|
| 1995 |
Borrel MN, Fiallo M, Priebe W, Garnier-Suillerot A. P-glycoprotein-mediated efflux of hydroxyrubicin, a neutral anthracycline derivative, in resistant K562 cells. Febs Letters. 356: 287-99. PMID 7805856 DOI: 10.1016/0014-5793(94)01282-2 |
0.303 |
|
| 1995 |
Ling YH, Zou Y, Priebe W, Perez-Soler R. Partial circumvention of multi-drug resistance by annamycin is associated with comparable inhibition of DNA synthesis in the nuclear matrix of sensitive and resistant cells. International Journal of Cancer. 61: 402-8. PMID 7729954 DOI: 10.1002/Ijc.2910610321 |
0.314 |
|
| 1995 |
Lothstein L, Sweatman TW, Priebe W. Hydroxylation at C-3′ of doxorubicin alters the selected phenotype of cellular drug resistance Bioorganic and Medicinal Chemistry Letters. 5: 1807-1812. DOI: 10.1016/0960-894X(95)00300-I |
0.323 |
|
| 1994 |
Perez-Soler R, Ling YH, Zou Y, Priebe W. Cellular pharmacology of the partially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-V1 cells. Cancer Chemotherapy and Pharmacology. 34: 109-18. PMID 8194162 DOI: 10.1007/Bf00685927 |
0.339 |
|
| 1994 |
Priebe W, Perez-Soler R. Design and tumor targeting of anthracyclines able to overcome multidrug resistance: a double-advantage approach. Pharmacology & Therapeutics. 60: 215-34. PMID 8022858 DOI: 10.1016/0163-7258(93)90007-Z |
0.324 |
|
| 1994 |
Solary E, Ling YH, Perez-Soler R, Priebe W, Pommier Y. Hydroxyrubicin, a deaminated derivative of doxorubicin, inhibits mammalian DNA topoisomerase II and partially circumvents multidrug resistance. International Journal of Cancer. 58: 85-94. PMID 8014019 DOI: 10.1002/Ijc.2910580115 |
0.347 |
|
| 1994 |
Perez-soler R, Zou Y, Ling Y, Priebe W. The Use of Liposomes as Carriers of Lipophilic Anthracycline Antibiotics Journal of Liposome Research. 4: 555-573. DOI: 10.3109/08982109409037061 |
0.305 |
|
| 1993 |
Priebe W, Van NT, Burke TG, Perez-Soler R. Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity. Anti-Cancer Drugs. 4: 37-48. PMID 8457713 DOI: 10.1097/00001813-199302000-00005 |
0.364 |
|
| 1993 |
Horton D, Issa M, Priebe W, Sznaidman ML. Synthesis of 3-deoxyaldulosonic acid esters by one-carbon chain extension of glycal-derived lactone precursors. Carbohydrate Research. 246: 105-18. PMID 8370034 DOI: 10.1016/0008-6215(93)84027-4 |
0.475 |
|
| 1993 |
Horton D, Priebe W, Sznaidman ML, Varela O. Synthesis and antitumor activity of anthracycline disaccharide glycosides containing daunosamine Journal of Antibiotics. 46: 1720-1730. PMID 8270495 DOI: 10.7164/Antibiotics.46.1720 |
0.454 |
|
| 1993 |
Horton D, Priebe W, Sznaidman ML. Steric and conformational effects in the dehalogenation of 2-halo sugar derivatives with tributylstannane The Journal of Organic Chemistry. 58: 1821-1826. DOI: 10.1021/Jo00059A037 |
0.455 |
|
| 1992 |
Perez-Soler R, Priebe W. Liposomal formulation and antitumor activity of 14-O-palmitoyl-hydroxyrubicin. Cancer Chemotherapy and Pharmacology. 30: 267-71. PMID 1643693 DOI: 10.1007/Bf00686293 |
0.336 |
|
| 1992 |
Priebe W, Neamati N, Perez-soler R. 3'-Hydroxyesorubicin halogenated at C-2'. The Journal of Antibiotics. 45: 386-93. PMID 1577666 DOI: 10.7164/Antibiotics.45.386 |
0.558 |
|
| 1992 |
Priebe W, Grynkiewicz G, Neamati N. One step C-acylation of glycals and 2-deoxy-hexopyranoses at C-2 Tetrahedron Letters. 33: 7681-7684. DOI: 10.1016/0040-4039(93)88015-B |
0.528 |
|
| 1991 |
Priebe W, Grynkiewicz G, Neamati N, Perez-Soler R. A facile method for preparation of 3-thio-sugars and 3-thio-glycals. synthesis of 3′-mercapto-3′-deamino-doxorubicin Tetrahedron Letters. 32: 3313-3316. DOI: 10.1016/S0040-4039(00)92694-7 |
0.538 |
|
| 1991 |
Priebe W, Grynkiewicz G, Neamati N. 2-Deoxy-1-O-silylated-β-hexopyranoses. Useful glycosyl donors and synthetic intermediates. Tetrahedron Letters. 32: 2079-2082. DOI: 10.1016/S0040-4039(00)71241-X |
0.516 |
|
| 1991 |
Priebe W, Grynkiewicz G, Neamati N. Synthesis of new 1-C-(2-furyl)-and 3-C-(2-furyl)-hexopyranosides and 3-C-(2-furyl)-daunorubicin analogs Monatshefte F�R Chemie Chemical Monthly. 122: 419-423. DOI: 10.1007/Bf00809663 |
0.489 |
|
| 1990 |
Priebe W, Neamati N, Perez-Soler R. 3'-Hydroxyesorubicin. Synthesis and antitumor activity. The Journal of Antibiotics. 43: 838-46. PMID 2387778 DOI: 10.7164/Antibiotics.43.838 |
0.567 |
|
| 1990 |
Horton D, Priebe W, Sznaidman M. Iodoalkoxylation of 1,5-anhydro-2-deoxy-hex-1-enitols (glycals). Carbohydrate Research. 205: 71-86. PMID 2276153 DOI: 10.1016/0008-6215(90)80129-Q |
0.499 |
|
| 1989 |
Horton D, Priebe W, Sznaidman M. A new approach to 2-deoxyglycosides permitting access to anthracycline glycosides specifically labeled at the 2'-position. Carbohydrate Research. 187: 149-53. PMID 2752389 DOI: 10.1016/0008-6215(89)80063-1 |
0.439 |
|
| 1989 |
Horton D, Priebe W, Sznaidman M. Preparation of 4-O-acetyl-1,5-anhydro-2,3,6-trideoxy-3-trifluoroacetamido-L- lyxo-hex-1-enitol, a key intermediate in synthesis of daunosamine glycosides. Carbohydrate Research. 187: 145-8. PMID 2752388 DOI: 10.1016/0008-6215(89)80062-X |
0.51 |
|
| 1988 |
Horton D, Priebe W, Sznaidman M. Preparative procedures for conversion of daunorubicin into doxorubicin (Adriamycin) and 14-O-acetyldoxorubicin by way of 14-bromodaunorubicin. Carbohydrate Research. 184: 231-5. PMID 3242811 DOI: 10.1016/0008-6215(88)80021-1 |
0.473 |
|
| 1987 |
Chmielewski M, Jurczak J, Priebe W, Horton D. Reverse anomeric effect of the carbamoyl group of 2,6-disubstituted 6-carbamoyl-5,6-dihydro-2H-pyrans Magnetic Resonance in Chemistry. 25: 161-165. DOI: 10.1002/Mrc.1260250215 |
0.452 |
|
| 1986 |
Horton D, Priebe W, Varela O. Halogenation of 1,5-anhydrohex-1-enitols (glycals). Influence of the C-6 substituent The Journal of Organic Chemistry. 51: 3479-3485. DOI: 10.1021/Jo00368A015 |
0.492 |
|
| 1986 |
Horton D, Priebe W, Varela O. Synthesis and Antitumor Activity of 2′-Bromo- and 2′-Chloro-3′-acetoxy- 3′-deaminodaunorubicin Analogs. Cheminform. 17. DOI: 10.1002/Chin.198623359 |
0.49 |
|
| 1986 |
Horton D, Priebe W, Varela O. Selective Silylation of 6-Deoxyglycals. Cheminform. 17. DOI: 10.1002/Chin.198623328 |
0.429 |
|
| 1986 |
Bhate P, Horton D, Priebe W. Allylic Rearrangement of 6-Deoxyglycals Having Practical Utility. Cheminform. 17. DOI: 10.1002/Chin.198623327 |
0.433 |
|
| 1985 |
Bhaté P, Horton D, Priebe W. Allylic rearrangement of 6-deoxyglycals having practical utility. Carbohydrate Research. 144: 331-7. PMID 4092212 DOI: 10.1016/S0008-6215(00)90681-5 |
0.433 |
|
| 1985 |
Horton D, Priebe W, Varela O. Selective acylation of 6-deoxyglycals Carbohydrate Research. 144: 317-324. PMID 4092210 DOI: 10.1016/S0008-6215(00)90679-7 |
0.494 |
|
| 1985 |
Horton D, Priebe W, Varela O. Synthesis and antitumor activity of 2′-bromo- and 2′-chloro-3′-acetoxy-3′-deaminodaunorubicin analogs Carbohydrate Research. 144: 305-315. PMID 4092209 DOI: 10.1016/S0008-6215(00)90678-5 |
0.495 |
|
| 1985 |
Cheung TM, Horton D, Priebe W, Turner WR, Weckerle W. Sugar-ring analogs of daunorubicin: 3'-epidaunorubicin, 3'-hydroxy-3',5'-diepidaunorubicin and 3',6'-dihydroxy-3',5'-diepidaunorubicin. The Journal of Antibiotics. 38: 683-6. PMID 4019314 DOI: 10.7164/Antibiotics.38.683 |
0.384 |
|
| 1985 |
Horton D, Priebe W. Oxyhalogenation of glycals for the synthesis of anti-tumor-active 2'-halo daunorubicin analogs. Carbohydrate Research. 136: 391-6. PMID 4005892 DOI: 10.1016/0008-6215(85)85212-5 |
0.522 |
|
| 1984 |
Horton D, Priebe W, Varela O. 3'-Deamino-4'-epi-3'-hydroxy-daunorubicin and -doxorubicin. Synthesis and antitumor activity Journal of Antibiotics. 37: 1635-1641. PMID 6549317 DOI: 10.7164/Antibiotics.37.1635 |
0.449 |
|
| 1984 |
Horton D, Priebe W, Varela O. Synthesis and antitumor activity of 3'-deamino-3'-hydroxydoxorubicin. A facile procedure for the preparation of doxorubicin analogs Journal of Antibiotics. 37: 853-858. PMID 6548219 DOI: 10.7164/Antibiotics.37.853 |
0.492 |
|
| 1984 |
Horton D, Priebe W, Varela O. Synthesis of antitumor-active (7S,9S)-4-demethoxy-7-O-(2,6-dideoxy-2-iodo-α-l-mannopyranosyl)adriamycinone: Preparative resolution of a racemic anthracyclinone by alkoxyhalogenation of a glycal Carbohydrate Research. 130. DOI: 10.1002/Chin.198452373 |
0.503 |
|
| 1983 |
Horton D, Priebe W. 14-esters of 7-O-(3,4-di-O-acetyl-2,6-dideoxy-alpha-L-lyxo-hexopyranosyl)adriamycinone: synthesis and antitumor activity. The Journal of Antibiotics. 36: 1211-5. PMID 6630080 DOI: 10.7164/Antibiotics.36.1211 |
0.486 |
|
| 1981 |
Horton D, Priebe W. New adriamycin analogs. Synthesis and antitumor activity of 14-substituted 7-O-(3,4-di-O-acetyl-2,6-dideoxy-alpha-L-lyxo-hexopyranosyl)daunomycinones. The Journal of Antibiotics. 34: 1019-25. PMID 7319917 DOI: 10.7164/Antibiotics.34.1019 |
0.47 |
|
| 1981 |
Horton D, Priebe W, Turner WR. Synthesis and antitumor activity of 7-O-(3,4-di-O-acetyl-2,6-dideoxy-alpha-L-lyxo-hexopyranosyl)adriamycinone. Carbohydrate Research. 94: 11-25. PMID 7260960 DOI: 10.1016/S0008-6215(00)85592-5 |
0.526 |
|
| 1981 |
Horton D, Priebe W. Synthetic routes to higher-carbon sugars. Reaction of lactones with 2-lithio-,3-dithiane Carbohydrate Research. 94: 27-41. DOI: 10.1016/S0008-6215(00)85593-7 |
0.486 |
|
| Show low-probability matches. |
